Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
McKinsey
Moodys
AstraZeneca

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR INOMAX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Inomax

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00041548 ↗ Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation Terminated Mallinckrodt Phase 1/Phase 2 2002-05-01 The purpose of this pilot study is to evaluate whether administration of nitric oxide (NO)gas by oxygen hood at 20 ppm significantly increases PaO2, as compared to placebo gas (oxygen), within one hour of initiation and with no significant adverse effects.
NCT00041574 ↗ Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide Terminated Mallinckrodt Phase 2 2002-04-01 The purpose of this program is to evaluate the logistic issues and patient requirements for chronic pulsed INOmax delivery in ambulatory, home-care patients. To understand patient needs, patients with a variety of underlying diseases will be included. Safety of chronic therapy will be monitored by serial measurements of methemoglobin, platelet function assay and reported adverse events.
NCT00060840 ↗ The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation Completed Mallinckrodt Phase 2 2003-07-01 The purpose of this study is to assess the utility of nitric oxide for inhalation during left ventricular assist device (LVAD) implantation following cardiopulmonary bypass (CPB). This is to be assessed by the number of patients in each treatment group meeting failure criteria within 24 hours on study drug, as defined by two or more of the following: - Left ventricular flow rate index (LVFRI) ≤ 2.0 L/min/m^2 - Administration of ≥ 20 inotropic equivalents (IE) - 10 µg/kg/min dopamine, dobutamine, enoximone or amrinone is equivalent to 10 IE - 0.1 µg/kg/min epinephrine or norepinephrine is equivalent to 10 IE - 1 µg/kg/min milrinone is equivalent to 15 IE - 0.1 U/min vasopressin is equivalent to 10 IE - Mean arterial pressure (MAP) ≤ 55 mmHg - Central venous pressure (CVP) ≥ 16 mmHg - Percent mixed venous oxygen saturation (SvO2) ≤ 55% Or at least one of the following criteria: - Failure to wean from cardiopulmonary bypass at least once due to hemodynamic failure. Re-initiation of cardiopulmonary bypass to correct bleeding or other technical issues will not be considere 'failure to wean' - Death
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Inomax

Condition Name

Condition Name for Inomax
Intervention Trials
Lung Disease 2
Sickle Cell Disease 2
Hypoxemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Inomax
Intervention Trials
Hypertension, Pulmonary 3
Anemia, Sickle Cell 3
Inflammation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Inomax

Trials by Country

Trials by Country for Inomax
Location Trials
United States 44
Canada 3
Germany 2
Poland 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Inomax
Location Trials
California 4
New Jersey 3
Colorado 3
Ohio 3
Alabama 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Inomax

Clinical Trial Phase

Clinical Trial Phase for Inomax
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Inomax
Clinical Trial Phase Trials
Completed 7
Terminated 4
Withdrawn 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Inomax

Sponsor Name

Sponsor Name for Inomax
Sponsor Trials
Mallinckrodt 11
University of Colorado, Denver 1
Assistance Publique - Hôpitaux de Paris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Inomax
Sponsor Trials
Industry 11
Other 9
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
Boehringer Ingelheim
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.